ventoline 5 mg ml nebuliser solution - search results

United States - English - NLM (National Library of Medicine)

ventolin hfa- albuterol sulfate aerosol, metered

direct rx - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - 1.1 bronchospasm ventolin hfa inhalation aerosol is indicated for the treatment or prevention of bronchospasm in patients aged 4 years and older with reversible obstructive airway disease. 1.2 exercise-induced bronchospasm ventolin hfa is indicated for the prevention of exercise-induced bronchospasm in patients aged 4 years and older. ventolin hfa is contraindicated in patients with a history of hypersensitivity to any of the ingredients [see warnings and precautions (5.6), description (11)]. 8.1 pregnancy pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to asthma medications during pregnancy. for more information, contact the mothertobaby pregnancy studies conducted by the organization of teratology information specialists at 1‑877-311-8972 or visit https://mothertobaby.org/ongoing-study/asthma/. risk summary there are no randomized clinical studies of use of albuterol sulfate during pregnancy. available data from epidemiological studies and

Australia - English - Department of Health (Therapeutic Goods Administration)

ventolin obstetric injection

glaxosmithkline australia pty ltd - salbutamol sulfate -

New Zealand - English - Medsafe (Medicines Safety Authority)

ventolin

glaxosmithkline nz limited - salbutamol sulfate 120.5ug equivalent to 100 µg dose (10% excess may be added to compensate for manufacturing loss); - aerosol inhaler, metered dose - 100 mcg/dose - active: salbutamol sulfate 120.5ug equivalent to 100 µg dose (10% excess may be added to compensate for manufacturing loss) excipient: norflurane - salbutamol is a selective ?2 adrenoceptor agonist indicated for the treatment or prevention of bronchospasm. it provides short acting (four hours) bronchodilation in reversible airways obstruction due to asthma, chronic bronchitis and emphysema. for patients with asthma salbutamol may be used to relieve symptoms when they occur and to prevent them prior to a known trigger. bronchodilators should not be the only or main treatment in patients with persistent asthma. in patients with persistent asthma unresponsive to salbutamol, treatment with inhaled corticosteroids is recommended to achieve and maintain control. failure to respond promptly or fully to such rescue medication signals a need for urgent medical advice and treatment.

Australia - English - Department of Health (Therapeutic Goods Administration)

ventolin inhaler cfc-free salbutamol 100 microgram (as sulfate) pressurised inhaler metered dose (with counter)

glaxosmithkline australia pty ltd - salbutamol sulfate, quantity: 120.5 microgram/actuation (equivalent: salbutamol, qty 100 microgram/actuation) - inhalation, pressurised - excipient ingredients: norflurane - other conditions: do not puncture or incinerate even when empty as canister may explode. indications: for the relief of bronchospasm in patients with asthma or chronic obstructive pulmonary disease, and for acute prophylaxis against exercise-induced asthma and other stimuli known to induce bronchospasm.

Namibia - English - Namibia Medicines Regulatory Council

ventoline nebules 2.5mg

glaxosmithkline s.a (pty) ltd - salbutamol sulphate - solution for inhalation - each 2.5ml ampoules contain salbutamol sulphate equiv. to salbutamol 2.5mg

Namibia - English - Namibia Medicines Regulatory Council

ventoline nebules 5mg

glaxosmithkline s.a (pty) ltd - salbutamol sulphate - solution for inhalation - each 2.5ml ampoules contain salbutamol sulphate equiv. to salbutamol 5mg